EN عنوان مقاله | Protective effects of gabapentin against the seizure susceptibility and comorbid behavioral abnormalities in the early socially isolated mice |
---|---|
نویسندگان | Shayan Amiri a b c 1 , Arya Haj-Mirzaian a b,1, Hossein Amini-Khoei d e , Ali Razmi f , Armin Shirzadian a b , Maryam Rahimi-Balaei g , Carl O. Olson c , Arman Mohsenzadeh a , Mojgan Rastegar c , Mohammad-Reza Zarrindast a, Mahmoud Ghazi-Khansari |
نشریه | European Journal of Pharmacology |
شماره صفحات | 106 |
صفحه پايان | 114 |
نوع مقاله | Full Paper |
تاریخ انتشار | February 2017 |
رتبه نشریه | ISI |
نوع نشریه | چاپی |
کشور محل چاپ | آروبا |
چکیده مقاله
Adolescence is a pivotal period of brain development during lifespan, which is sensitive to stress exposure. Early social isolation stress (SIS) is known to provoke a variety of psychiatric comorbidities as well as seizure risk. Psychiatric comorbidities present challenging dilemmas for treatment and management in people with seizure disorders. In this study, we aimed to investigate whether gabapentin (GBP) as an anti-epileptic drug is able to alleviate the seizure activity as well as comorbid behavioral abnormalities in socially isolated mice. Results showed that early SIS induced proconvulsant effects along with depressive, aggressive and anxiety-like behaviors. Whereas the administration of both acute and chronic GBP at sub-effective doses produced no alterations in the behavioral profile of socially conditioned counterparts the same treatments effectively reversed the seizure susceptibility to pentylenetetrazole and behavioral deficits in isolated mice. Results of the study indicate that 1) Early SIS could be considered as an animal model of psychosocial stress to investigate the psychiatric comorbidities in seizure disorders, 2) Chronic administration of low dose GBP prevented the shaping of behavioral abnormalities in adulthood, 3) Chronic administration of low dose GBP produced no negative behavioral effects in socially conditioned mice suggesting the safety of the drug, 4) Gabapentin at low doses may be considered as an agent for management of epilepsy in individuals with psychiatric comorbidities.